BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17959343)

  • 1. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
    Simpson DM; Estanislao L; Brown SJ; Sampson J
    J Pain Symptom Manage; 2008 Mar; 35(3):299-306. PubMed ID: 17959343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
    Simpson DM; Gazda S; Brown S; Webster LR; Lu SP; Tobias JK; Vanhove GF;
    J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
    Simpson DM; Brown S; Tobias J;
    Neurology; 2008 Jun; 70(24):2305-13. PubMed ID: 18541884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
    Backonja MM; Malan TP; Vanhove GF; Tobias JK;
    Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
    Babbar S; Marier JF; Mouksassi MS; Beliveau M; Vanhove GF; Chanda S; Bley K
    Ther Drug Monit; 2009 Aug; 31(4):502-10. PubMed ID: 19494795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J;
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
    Simpson DM; Brown S; Tobias JK; Vanhove GF;
    Clin J Pain; 2014 Feb; 30(2):134-42. PubMed ID: 23446088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
    Noto C; Pappagallo M; Szallasi A
    Curr Opin Investig Drugs; 2009 Jul; 10(7):702-10. PubMed ID: 19579176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy.
    Herrmann DN; Barbano RL; Hart-Gouleau S; Pennella-Vaughan J; Dworkin RH
    Pain Med; 2005; 6(5):379-84. PubMed ID: 16266359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Webster LR; Malan TP; Tuchman MM; Mollen MD; Tobias JK; Vanhove GF
    J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
    Webster LR; Peppin JF; Murphy FT; Lu B; Tobias JK; Vanhove GF
    Diabetes Res Clin Pract; 2011 Aug; 93(2):187-197. PubMed ID: 21612836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.
    Webster LR; Tark M; Rauck R; Tobias JK; Vanhove GF
    BMC Neurol; 2010 Oct; 10():92. PubMed ID: 20937130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
    Irving G; Backonja M; Rauck R; Webster LR; Tobias JK; Vanhove GF
    Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
    Jones VM; Moore KA; Peterson DM
    J Pain Palliat Care Pharmacother; 2011; 25(1):32-41. PubMed ID: 21426216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy.
    Clifford DB; Simpson DM; Brown S; Moyle G; Brew BJ; Conway B; Tobias JK; Vanhove GF;
    J Acquir Immune Defic Syndr; 2012 Feb; 59(2):126-33. PubMed ID: 22067661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
    Mankowski C; Poole CD; Ernault E; Thomas R; Berni E; Currie CJ; Treadwell C; Calvo JI; Plastira C; Zafeiropoulou E; Odeyemi I
    BMC Neurol; 2017 Apr; 17(1):80. PubMed ID: 28431564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.
    Kennedy WR; Vanhove GF; Lu SP; Tobias J; Bley KR; Walk D; Wendelschafer-Crabb G; Simone DA; Selim MM
    J Pain; 2010 Jun; 11(6):579-87. PubMed ID: 20400377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials.
    Brown S; Simpson DM; Moyle G; Brew BJ; Schifitto G; Larbalestier N; Orkin C; Fisher M; Vanhove GF; Tobias JK
    AIDS Res Ther; 2013 Jan; 10(1):5. PubMed ID: 23351618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Irving GA; Backonja MM; Dunteman E; Blonsky ER; Vanhove GF; Lu SP; Tobias J;
    Pain Med; 2011 Jan; 12(1):99-109. PubMed ID: 21087403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study.
    Vinik AI; Perrot S; Vinik EJ; Pazdera L; Jacobs H; Stoker M; Long SK; Snijder RJ; van der Stoep M; Ortega E; Katz N
    BMC Neurol; 2016 Dec; 16(1):251. PubMed ID: 27919222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.